GSK 2857916

Drug Profile

GSK 2857916

Alternative Names: GSK-2857916; J6M0-mcMMAF

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 03 Dec 2016 Interim efficacy and adverse events data from a phase I trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Jul 2014 Phase-I clinical trials in Multiple myeloma in United Kingdom, Canada (IV) after July 2014
  • 01 Jul 2014 Phase-I clinical trials in Multiple myeloma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top